Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s | Zendy

Sahera DirajlalFargo | Zendy; Carlee Moser | Zendy; Todd T. Brown | Zendy; Theodoros Kelesidis | Zendy; Michael P. Dubé | Zendy; James H. Stein | Zendy; Judith S. Currier | Zendy; Grace A. McComsey | Zendy

Open Access

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s

Author(s) -

Sahera DirajlalFargo,

Carlee Moser,

Todd T. Brown,

Theodoros Kelesidis,

Michael P. Dubé,

James H. Stein,

Judith S. Currier,

Grace A. McComsey

Publication year - 2016

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofw174

Subject(s) - raltegravir , medicine , insulin resistance , emtricitabine , ritonavir , elvitegravir , homeostatic model assessment , darunavir , gastroenterology , atazanavir , randomized controlled trial , insulin , endocrinology , viral load , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy

HIV-infected treatment-naive participants were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) over 96 weeks. Insulin resistance increased rapidly and then plateaued and no differences were found with RAL when compared to ATV/r or DRV/r.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research